Back to Market返回行情

CTEV Claritev Corporation

USHealthcare
$31.24-5.05%ClosedMarket Cap: $532.6M

As of 2026-07-10 16:00

Why CTEV matters now

Claritev Corporation (CTEV) is a US stock in Healthcare. The latest InvestLog snapshot shows $31.24 with -5.05% on the session and $532.6M in market capitalization; recent performance reads 1-month +81.60% and YTD -31.18%.

The latest financial table shown here is Q1 2026, with revenue of $244.7M, net income of $-73.6M, and EPS of $-4.41. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.7%.

The latest indexable market news headline is "Claritev Rises to Leader Ranking in Everest Group's 2026 Pre-Payment Integrity Solutions PEAK Matrix® Assessment" from Business Wire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $34.00; recent insider activity includes Carol Nutter filing P-Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

-2.04

P/S

0.51

EV/EBITDA

9.84

DCF Value

$124.87

FCF Yield

-7.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

61.1%

Operating Margin

4.3%

Net Margin

-29.3%

ROE

205.8%

ROA

-5.9%

ROIC

0.8%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$244.7M$-73.6M$-4.41
Q4 2025$246.6M$-80.6M$-4.88
FY 2025$965.4M$-284.3M$-17.30
Q3 2025$246.0M$-69.8M$-4.23

Analyst Ratings

Consensus

Buy

Target (Consensus)

$39.25

Target (Median)

$34.00

Target Range

$28.00 - $61.00

Strong Buy: 2Buy: 3Hold: 1Sell: 0Strong Sell: 0
Wells FargoEqual Weight
2026-03-19
CitigroupBuy
2026-02-25
GuggenheimBuy
2026-02-24
CitigroupBuy
2026-01-09
CitigroupBuy
2025-11-10

Trading Activity

Insider Trades

Carol Nutterofficer: SVP, Chief People Officer
Buy2026-06-10
Prince John Michaeldirector
Buy2026-05-19
Dalton Travisdirector, officer: Pres., CEO & Executive Chair
Buy2026-05-19
Dalton Travisdirector, officer: Pres., CEO & Executive Chair
Buy2026-05-19
Kim Michaelofficer: EVP, Chief Digital Officer
Buy2026-05-19

Company Info

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Country

US

Exchange

Beta

0.77

Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.